Epilepsy and brain tumors

Area of Science:

• Neuro-oncology
• Epileptology

Background:

• Seizures and epilepsy are common complications in patients with brain tumors, significantly affecting their quality of life.
• Understanding seizure prevalence, predictors, and post-resection outcomes is crucial for effective brain tumor management.

Purpose of the Study:

• To review the incidence and predictors of seizures in various brain tumor types.
• To evaluate the likelihood of achieving seizure freedom after surgical tumor resection.
• To provide guidance on anticonvulsant medication selection in brain tumor patients.

Main Methods:

• Literature review of studies on seizures associated with brain tumors.
• Analysis of seizure rates across different brain tumor histologies and locations.
• Examination of factors predicting seizure control post-resection and medication management.

Main Results:

• Glioneuronal tumors (70-80%) and gliomas (60-75%) have the highest seizure rates, particularly with frontotemporal/insular involvement.
• Meningiomas (20-50%) and brain metastases (20-35%) also present with significant seizure risks.
• Approximately 60-90% of patients achieve seizure freedom post-resection, with gross total resection and early surgery being favorable predictors.

Conclusions:

• Seizure freedom is an achievable goal in brain tumor patients, significantly improving quality of life.
• Tailored anticonvulsant therapy, avoiding drug interactions (e.g., with chemotherapy), is essential.
• Further research into optimal seizure management strategies in neuro-oncology is warranted.